An international group of companies, the world leader in the market of drugs for the treatment of diabetes. More than 47,000 employees work in 80 company branches around the world. Products are supplied to more than 170 countries, production facilities are located in 16 countries on 5 continents.
The Novo Nordisk plant in the Kaluga region started producing finished products in 2015. It has a high-tech production base for the manufacture of a complete portfolio of modern insulins. In 2017, a new workshop was built to produce pre-filled FlexPen® syringes. A license was obtained from the Ministry of Industry and Trade of the Russian Federation for the production of finished dosage forms. Since 2018, mass production of modern drugs has started on the full-cycle principle. The total investment in production for the entire period exceeded 8 billion rubles.
The priority task of Novo Nordisk in Russia is to increase the availability of modern drugs and improve the quality of life of Russian patients.
Address: Kaluga, 2nd Avtomobilny pr., 1
